Prime Medicine (PRME) Research & Development (2021 - 2026)
Prime Medicine's (PRME) quarterly Research & Development came in at $34.1 million in Q1 2026, down 15.92% YoY from $40.6 million in Q1 2025, and down 1.74% on a QoQ basis from $34.7 million in Q4 2025.
Prime Medicine (PRME) Research & Development (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Research & Development data on file, last reported at $34.1 million in Q1 2026.
- Quarterly Research & Development fell 15.92% year-over-year to $34.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.2 million (down 2.47% YoY) and the FY2025 annual result came in at $160.6 million, up 3.44% from the prior year.
- Research & Development slipped to $34.1 million in Q1 2026, from $34.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $44.0 million in Q3 2025 to a low of $13.7 million in Q1 2022.
- A 5-year average of $34.4 million and a median of $34.7 million in 2025 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 238.47% in 2022, down 45.05% in 2022.
- Tracing PRME's Research & Development over 5 years: stood at $29.1 million in 2022, then jumped by 42.66% to $41.5 million in 2023, then dropped by 17.74% to $34.1 million in 2024, then increased by 1.77% to $34.7 million in 2025, then dropped by 1.74% to $34.1 million in 2026.
- The last three Research & Development figures came in at $34.1 million (Q1 2026), $34.7 million (Q4 2025), and $44.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 33.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.40 Mn |
| Mar 31, 2026 | 34.11 Mn |
| Dec 31, 2025 | 34.71 Mn |
| Sep 30, 2025 | 43.99 Mn |
| Jun 30, 2025 | 41.38 Mn |
| Mar 31, 2025 | 40.56 Mn |
| Dec 31, 2024 | 34.10 Mn |
| Sep 30, 2024 | 40.34 Mn |
| Jun 30, 2024 | 43.07 Mn |
| Mar 31, 2024 | 37.77 Mn |
| Dec 31, 2023 | 41.46 Mn |
| Sep 30, 2023 | 40.97 Mn |
| Jun 30, 2023 | 34.60 Mn |
| Mar 31, 2023 | 30.88 Mn |
| Dec 31, 2022 | 29.06 Mn |
| Sep 30, 2022 | 25.05 Mn |
| Jun 30, 2022 | 18.94 Mn |
| Mar 31, 2022 | 13.68 Mn |
| Dec 31, 2021 | 52.89 Mn |
| Sep 30, 2021 | 7.40 Mn |